A tüdocombining double acute accent neuroendokrin daganatainak tünetei és diagnosztikája

Translated title of the contribution: Symptoms and diagnostics of lung neuroendocrine tumors

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pulmonary neuroendocrine tumors comprise 20% of all lung cancers. They are separated into 4 subgroups: typical carcinoid tumor, atypical carcinoid tumor, large-cell neuroendocrine carcinoma, and small-cell lung carcinoma. The major symptoms present in 60% of patients are cough, hemoptysis, and obstructive pneumonia. They may also exhibit hormonally related symptoms e.g. carcinoid syndrome. Small cell lung cancer is the most common subgroup, with rapid progression, aggressive metastatic potential and the worst prognosis. Large cell neuroendocrine carcinoma is rare but also has a poor prognosis. Typical carcinoid may be accompanied with hormone related symptoms and has the best prognosis; atypical one on the contrary may cause lymph node and distant metastases in half of the cases. Elevated plasma levels of chromogranin-A are present in majority of pulmonary neuroendocrine tumors and act as tumor marker. The mainstay of treatment is radical surgery if possible. In locally advanced or metastatic disease combination chemotherapy and somatostatin-analogues may have beneficial effect. This review focuses on the general features, and current diagnostic options of pulmonary neuroendocrine tumors.

Original languageHungarian
Pages (from-to)366-370
Number of pages5
JournalOrvosi Hetilap
Volume152
Issue number10
DOIs
Publication statusPublished - Mar 1 2011

Fingerprint

Neuroendocrine Tumors
Carcinoid Tumor
Neuroendocrine Carcinoma
Large Cell Carcinoma
Lung
Small Cell Lung Carcinoma
Chromogranin A
Hemoptysis
Tumor Biomarkers
Somatostatin
Combination Drug Therapy
Cough
Lung Neoplasms
Pneumonia
Lymph Nodes
Hormones
Neoplasm Metastasis
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A tüdocombining double acute accent neuroendokrin daganatainak tünetei és diagnosztikája. / Tamási, L.; Müller, V.

In: Orvosi Hetilap, Vol. 152, No. 10, 01.03.2011, p. 366-370.

Research output: Contribution to journalArticle

@article{e54a1e8c14ad4728902303e22369cf89,
title = "A t{\"u}docombining double acute accent neuroendokrin daganatainak t{\"u}netei {\'e}s diagnosztik{\'a}ja",
abstract = "Pulmonary neuroendocrine tumors comprise 20{\%} of all lung cancers. They are separated into 4 subgroups: typical carcinoid tumor, atypical carcinoid tumor, large-cell neuroendocrine carcinoma, and small-cell lung carcinoma. The major symptoms present in 60{\%} of patients are cough, hemoptysis, and obstructive pneumonia. They may also exhibit hormonally related symptoms e.g. carcinoid syndrome. Small cell lung cancer is the most common subgroup, with rapid progression, aggressive metastatic potential and the worst prognosis. Large cell neuroendocrine carcinoma is rare but also has a poor prognosis. Typical carcinoid may be accompanied with hormone related symptoms and has the best prognosis; atypical one on the contrary may cause lymph node and distant metastases in half of the cases. Elevated plasma levels of chromogranin-A are present in majority of pulmonary neuroendocrine tumors and act as tumor marker. The mainstay of treatment is radical surgery if possible. In locally advanced or metastatic disease combination chemotherapy and somatostatin-analogues may have beneficial effect. This review focuses on the general features, and current diagnostic options of pulmonary neuroendocrine tumors.",
keywords = "carcinoid, diagnosis, lung, neuroendocrine tumor, symptoms",
author = "L. Tam{\'a}si and V. M{\"u}ller",
year = "2011",
month = "3",
day = "1",
doi = "10.1556/OH.2011.29041",
language = "Hungarian",
volume = "152",
pages = "366--370",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "10",

}

TY - JOUR

T1 - A tüdocombining double acute accent neuroendokrin daganatainak tünetei és diagnosztikája

AU - Tamási, L.

AU - Müller, V.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Pulmonary neuroendocrine tumors comprise 20% of all lung cancers. They are separated into 4 subgroups: typical carcinoid tumor, atypical carcinoid tumor, large-cell neuroendocrine carcinoma, and small-cell lung carcinoma. The major symptoms present in 60% of patients are cough, hemoptysis, and obstructive pneumonia. They may also exhibit hormonally related symptoms e.g. carcinoid syndrome. Small cell lung cancer is the most common subgroup, with rapid progression, aggressive metastatic potential and the worst prognosis. Large cell neuroendocrine carcinoma is rare but also has a poor prognosis. Typical carcinoid may be accompanied with hormone related symptoms and has the best prognosis; atypical one on the contrary may cause lymph node and distant metastases in half of the cases. Elevated plasma levels of chromogranin-A are present in majority of pulmonary neuroendocrine tumors and act as tumor marker. The mainstay of treatment is radical surgery if possible. In locally advanced or metastatic disease combination chemotherapy and somatostatin-analogues may have beneficial effect. This review focuses on the general features, and current diagnostic options of pulmonary neuroendocrine tumors.

AB - Pulmonary neuroendocrine tumors comprise 20% of all lung cancers. They are separated into 4 subgroups: typical carcinoid tumor, atypical carcinoid tumor, large-cell neuroendocrine carcinoma, and small-cell lung carcinoma. The major symptoms present in 60% of patients are cough, hemoptysis, and obstructive pneumonia. They may also exhibit hormonally related symptoms e.g. carcinoid syndrome. Small cell lung cancer is the most common subgroup, with rapid progression, aggressive metastatic potential and the worst prognosis. Large cell neuroendocrine carcinoma is rare but also has a poor prognosis. Typical carcinoid may be accompanied with hormone related symptoms and has the best prognosis; atypical one on the contrary may cause lymph node and distant metastases in half of the cases. Elevated plasma levels of chromogranin-A are present in majority of pulmonary neuroendocrine tumors and act as tumor marker. The mainstay of treatment is radical surgery if possible. In locally advanced or metastatic disease combination chemotherapy and somatostatin-analogues may have beneficial effect. This review focuses on the general features, and current diagnostic options of pulmonary neuroendocrine tumors.

KW - carcinoid

KW - diagnosis

KW - lung

KW - neuroendocrine tumor

KW - symptoms

UR - http://www.scopus.com/inward/record.url?scp=79952297410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952297410&partnerID=8YFLogxK

U2 - 10.1556/OH.2011.29041

DO - 10.1556/OH.2011.29041

M3 - Article

C2 - 21354952

AN - SCOPUS:79952297410

VL - 152

SP - 366

EP - 370

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 10

ER -